Literature DB >> 27325641

OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer.

Alexander A Svoronos1, Donald M Engelman2, Frank J Slack3.   

Abstract

MicroRNAs (miRNA) are short, noncoding RNAs whose dysregulation has been implicated in most, if not all, cancers. They regulate gene expression by suppressing mRNA translation and reducing mRNA stability. To this end, there is a great deal of interest in modifying miRNA expression levels for the treatment of cancer. However, the literature is fraught with inconsistent accounts as to whether various miRNAs are oncogenic or tumor suppressive. In this review, we directly examine these inconsistencies and propose several mechanisms to explain them. These mechanisms include the possibility that specific miRNAs can simultaneously produce competing oncogenic and tumor suppressive effects by suppressing both tumor suppressive mRNAs and oncogenic mRNAs, respectively. In addition, miRNAs can modulate tumor-modifying extrinsic factors, such as cancer-immune system interactions, stromal cell interactions, oncoviruses, and sensitivity to therapy. Ultimately, it is the balance between these processes that determines whether a specific miRNA produces a net oncogenic or net tumor suppressive effect. A solid understanding of this phenomenon will likely prove valuable in evaluating miRNA targets for cancer therapy. Cancer Res; 76(13); 3666-70. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27325641      PMCID: PMC4930690          DOI: 10.1158/0008-5472.CAN-16-0359

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Zhenghua Luo; Stefano Volinia; Laura Z Rassenti; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

2.  Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.

Authors:  Pierluigi Gasparini; Francesca Lovat; Matteo Fassan; Lucia Casadei; Luciano Cascione; Naduparambil K Jacob; Stefania Carasi; Dario Palmieri; Stefan Costinean; Charles L Shapiro; Kay Huebner; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

3.  miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

Authors:  Avital Gaziel-Sovran; Miguel F Segura; Raffaella Di Micco; Mary K Collins; Douglas Hanniford; Eleazar Vega-Saenz de Miera; John F Rakus; John F Dankert; Shulian Shang; Robert S Kerbel; Nina Bhardwaj; Yongzhao Shao; Farbod Darvishian; Jiri Zavadil; Adrian Erlebacher; Lara K Mahal; Iman Osman; Eva Hernando
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

4.  MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma.

Authors:  Chenglin Wu; Bo Jin; Liting Chen; Dexiang Zhuo; Zheng Zhang; Kan Gong; Zebin Mao
Journal:  Cell Signal       Date:  2013-02-15       Impact factor: 4.315

5.  Treatment of HCV infection by targeting microRNA.

Authors:  Harry L A Janssen; Hendrik W Reesink; Eric J Lawitz; Stefan Zeuzem; Maribel Rodriguez-Torres; Keyur Patel; Adriaan J van der Meer; Amy K Patick; Alice Chen; Yi Zhou; Robert Persson; Barney D King; Sakari Kauppinen; Arthur A Levin; Michael R Hodges
Journal:  N Engl J Med       Date:  2013-03-27       Impact factor: 91.245

6.  MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1.

Authors:  Wenxing Qin; Qiusheng Ren; Te Liu; Yongyi Huang; Jiejun Wang
Journal:  FEBS Lett       Date:  2013-03-20       Impact factor: 4.124

7.  MicroRNA-mediated drug resistance in breast cancer.

Authors:  Kristy R Kutanzi; Olga V Yurchenko; Frederick A Beland; Vasyl' F Checkhun; Igor P Pogribny
Journal:  Clin Epigenetics       Date:  2011-06-27       Impact factor: 6.551

8.  miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT.

Authors:  X Xiang; X Zhuang; S Ju; S Zhang; H Jiang; J Mu; L Zhang; D Miller; W Grizzle; H-G Zhang
Journal:  Oncogene       Date:  2011-04-04       Impact factor: 9.867

Review 9.  Diverse functions of miR-125 family in different cell contexts.

Authors:  Yu-Meng Sun; Kang-Yu Lin; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2013-01-15       Impact factor: 17.388

10.  Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth.

Authors:  Yuan Yin; Xing Cai; Xi Chen; Hongwei Liang; Yujing Zhang; Jing Li; Zuoyun Wang; Xiulan Chen; Wen Zhang; Seiji Yokoyama; Cheng Wang; Liang Li; Limin Li; Dongxia Hou; Lei Dong; Tao Xu; Takachika Hiroi; Fuquan Yang; Hongbin Ji; Junfeng Zhang; Ke Zen; Chen-Yu Zhang
Journal:  Cell Res       Date:  2014-09-16       Impact factor: 25.617

View more
  253 in total

1.  Expression of miRNA in 5-FU resistant esophageal cancer.

Authors:  Prasit Mahawongkajit; Prakitpunthu Tomtitchong
Journal:  Mol Clin Oncol       Date:  2020-06-11

2.  Altered microRNA expression patterns during the initiation and promotion stages of neonatal diethylstilbestrol-induced dysplasia/neoplasia in the hamster (Mesocricetus auratus) uterus.

Authors:  Ramesh Padmanabhan; Isabel R Hendry; Jennifer R Knapp; Bin Shuai; William J Hendry
Journal:  Cell Biol Toxicol       Date:  2017-03-06       Impact factor: 6.691

Review 3.  Epidrugs: targeting epigenetic marks in cancer treatment.

Authors:  Cristiana Libardi Miranda Furtado; Maria Claudia Dos Santos Luciano; Renan Da Silva Santos; Gilvan Pessoa Furtado; Manoel Odorico Moraes; Claudia Pessoa
Journal:  Epigenetics       Date:  2019-07-13       Impact factor: 4.528

4.  [miR-593 inhibits proliferation of colon cancer cells in vitro by down-regulating PLK1].

Authors:  Jinzhu Ma; Yiping Zhu; Zhen Wang; Jiawei Zan; Long Cao; Zunyong Feng; Senlin Wang; Qian Fan; Liang Yan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

5.  New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating Sestrin-2 in human bladder cancer.

Authors:  Xiaohui Hua; Jiheng Xu; Xu Deng; Jiawei Xu; Jingxia Li; David Q Zhu; Junlan Zhu; Honglei Jin; Zhongxian Tian; Haishan Huang; Qin-Shi Zhao; Chuanshu Huang
Journal:  Cancer Lett       Date:  2018-08-16       Impact factor: 8.679

6.  Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach.

Authors:  Chiara Bianca Maria Platania; Rosa Maisto; Maria Consiglia Trotta; Michele D'Amico; Settimio Rossi; Carlo Gesualdo; Giovanbattista D'Amico; Cornel Balta; Hildegard Herman; Anca Hermenean; Franca Ferraraccio; Iacopo Panarese; Filippo Drago; Claudio Bucolo
Journal:  Br J Pharmacol       Date:  2019-05-09       Impact factor: 8.739

7.  miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA.

Authors:  Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Paola Lucia Chiara Iervolino; Esther Imperlini; Annalisa Mandola; Anna Verde; Anna Elisa De Stefano; Katia Pane; Monica Franzese; Silvia Esposito; Fulvio Basolo; Stefania Orrù; Giuliana Salvatore
Journal:  Endocrine       Date:  2019-03-29       Impact factor: 3.633

8.  Role of TRPV4 in matrix stiffness-induced expression of EMT-specific LncRNA.

Authors:  Shweta Sharma; Li Ma; Shaik O Rahaman
Journal:  Mol Cell Biochem       Date:  2020-07-30       Impact factor: 3.396

Review 9.  Applications of pHLIP Technology for Cancer Imaging and Therapy.

Authors:  Linden C Wyatt; Jason S Lewis; Oleg A Andreev; Yana K Reshetnyak; Donald M Engelman
Journal:  Trends Biotechnol       Date:  2017-04-21       Impact factor: 19.536

10.  Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population.

Authors:  Zebo Huang; Wenjiao Chen; Yiping Du; Qin Guo; Yong Mao; Xin Zhou; Dong Hua
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-31       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.